(UBX) – FDA
-
UNITY Biotechnology (UBX) Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
-
UNITY Biotechnology (UBX) Reports 48-Week Results from Phase 2 ENVISION Study of UBX1325
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to UBX Stock Lookup